Immunis is a private biotechnology company researching and developing multi-active biologics to address age related diseases. Our investigational therapy, IMM01-STEM, leverages our leading-edge capabilities in cell culture to deliver a product of all natural, all human immune modulators in their natural relative concentrations. There is preclinical data supporting that IMM01-STEM benefits muscle regeneration and metabolism. Immunis is currently testing the effects of IMM01-STEM in a Phase 1/2a clinical trial for age-related muscle atrophy.